[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"endometrial-hyperplasia\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:endometrial-hyperplasia":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,11,0,[8,41,66,108,139,164,197,226,250,277,299],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100626527","phase-2-progestins-for-the-treatment-of-endometrial-cancer-or-precancers-of-the-uterus-before-surgery-the-pro-window-trial-100626527",false,"NCT07436793","Progestins for the Treatment of Endometrial Cancer or Precancers of the Uterus Before Surgery, The Pro-Window Trial","Evaluating Promising Progestins in Endometrial Cancer Through a Rotating Umbrella Surgical Window Trial - The PRO-WINDOW TRIAL for Endometrial Cancer","Inclusion Criteria:\n\n* Patients must have a histologically proven diagnosis of endometrioid endometrial adenocarcinoma by endometrial curettage or biopsy within 8 weeks prior to registration. Pathology reports should document adequate tissue from the biopsy and slides should be reasonable determined to be obtainable by the study team for study use\n* History\u002Fphysical examination within 42 +\u002F- 5 days of planned surgical procedure (18-21 days from day 1)\n* Age ≥ 18\n* The trial is open only to women with primary endometrioid adenocarcinoma of the uterine corpus (all histologic grades and stages) who are planned and appropriate for primary surgical treatment to include removal of the uterine corpus via any surgical modality. The patient must be considered a suitable surgical candidate\n* Patients must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, 2, or 3 within 28 days prior to registration\n* Formalin-fixed, paraffin-embedded tumor tissue from the biopsy or curettage must be reasonably deemed available for submission along with the corresponding pathology report\n* Platelets ≥ 100,000\u002Fμl\n* Granulocytes (absolute neutrophil count \\[ANC\\]) ≥ 1,500\u002Fμl\n* Creatinine ≤ 1.6 mg\u002Fdl\n* Serum glutamic-pyruvic transaminase (SGPT) (alanine transaminase \\[ALT\\]) ≤ 3 x upper limits of normal\n* Bilirubin within institutional normal limits\n* The patient must provide study-specific informed consent and authorization permitting release of personal health information prior to study entry\n* Any patients of childbearing potential must have a negative pregnancy test\n\nExclusion Criteria:\n\n* Patients with any non-endometrioid histology (such as serous, clear cell, or carcinosarcoma or mixed)\n* Patients who have received prior progestin or anti-estrogen therapy during the 3 months before the diagnosis of endometrioid adenocarcinoma of the uterine corpus is established. Estrogen therapy alone is allowed\n* Patients with ECOG performance status of 4\n* Patients with history of deep venous thrombosis or pulmonary embolism within the past 2 years or ongoing thromboembolic disorders\n* Patients who have previously received systemic, radiation or other treatment for uterine cancer\n* Patients for whom formalin-fixed, paraffin-embedded tumor tissue from the biopsy or curettage is scant or unavailable\n* Patients with a suspected or known peanut allergy\n* Patients with serious comorbidities or gastrointestinal obstruction that precludes taking oral medications or have malabsorptive disease","FEMALE","18 Years",{"count":19,"type":20},140,"ESTIMATED","INTERVENTIONAL",[23],"PHASE2","This phase II trial tests compares the effect of progestins, megestrol acetate to micronized progesterone, in treating patients with endometrial cancer and precancers of the uterus (atypical endometrial hyperplasia) before surgery. Progestins, similar to the natural hormone progesterone, are approved drugs used in birth control and hormone replacement pills, and some can treat uterine endometrial cancers. In the initial comparison of this rotating umbrella trial, megestrol acetate, a progestin, will be compared to micronized progesterone, a form of natural progesterone that is a hormone produced by body normally. Hormone therapy using megestrol acetate and micronized progesterone may be effective in treating patients with endometrial cancer or atypical endometrial hyperplasia before surgery, and understanding the tissue effects of each agent on the malignant endometrium will uncover novel mechanistic and biomarker data to understand how best to advanced hormone therapy for endometrial cancer.",[26,27],"Endometrial Endometrioid Adenocarcinoma","Endometrial Hyperplasia","RECRUITING","2026-06-30",{"date":31,"type":32},"2026-07-02","ACTUAL",{"date":34,"type":32},"2026-06-15",{"date":36,"type":20},"2031-06-30",{"name":38,"class":39},"New Mexico Cancer Research Alliance","OTHER",4,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":47,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":49,"targetDuration":4,"studyType":21,"phases":51,"briefSummary":53,"conditions":54,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":55,"lastUpdatePostDateStruct":56,"startDateStruct":58,"completionDateStruct":60,"leadSponsor":62,"locationsCount":65},"100585585","phase-3-mirena-for-the-treatment-of-nonatypical-endometrial-hyperplasia-for-6-months-100585585","NCT06904274","Mirena for the Treatment of Nonatypical Endometrial Hyperplasia for 6 Months","A Multi-center, Open Label, Randomized Parallel Group Study Evaluating the Proportion of Women With Complete Resolution of Nonatypical Endometrial Hyperplasia Treated With Mirena or Oral Medroxyprogesterone Acetate for 6 Months","SUNFLOWER","Inclusion Criteria:\n\n* Post-menarchal women (≥18 years) at the time of signing the informed consent.\n* Women with histologically confirmed NAEH independent of their parity or menopausal status. Endometrial samples will be obtained either at screening or no more than 42 days prior to the signing of the informed consent form.\n\nExclusion Criteria:\n\n* Any diseases or conditions that might interfere with the conduct of the study or the interpretation of the results.\n* Congenital or acquired uterine or cervical anomaly including fibroids, or cervical stenosis that in the opinion of the investigator, would interfere with insertion and\u002For retention of the intrauterine system (i.e., if they distort the uterine cavity).\n* Use of any long-acting injectable sex-hormone preparations within 6 months prior to the start of study intervention, and \u002For short acting hormonal medication within 6 weeks prior to the start of study intervention.\n* Pregnancy\n* Participants with either known family or personal history of genetic predisposition to uterine, ovarian or colorectal cancers (e.g. Lynch syndrome).",{"count":50,"type":20},207,[52],"PHASE3","Researchers are looking for a better way to treat women with nonatypical endometrial hyperplasia (NAEH).\n\nEndometrial hyperplasia is a condition where the lining of the uterus (called the endometrium) becomes too thick. Nonatypical means that the condition is not cancerous. It is often caused by hormone imbalances in women. Symptoms can include abnormal vaginal bleeding or irregular periods. If this condition is not treated, then it may lead to cancer.\n\nCurrently, there are no approved treatments for NAEH and that is why there is still an unmet medical need.\n\nThe study treatment, Mirena (also known as BAY 865028), is already available as a type of birth control device. It is inserted into the uterus where it gradually releases progesterone.\n\nIn this study, researchers want to find out if Mirena works for women with NAEH. They believe it can help by keeping hormone levels balanced in the body.\n\nThe main purpose of this study is to show that uterine lining goes back to completely normal lining after treatment with Mirena and that its use is safe in this population.\n\nFor this, the researchers will compare the number of participants with benign endometrium after 6 months of treatment with Mirena or oral MPA.\n\nThe study participants will be randomly assigned into one of two treatment groups. The randomization will be done 2:1 ratio, meaning that for every two participants assigned to Mirena, one will be assigned to oral medroxyprogesterone acetate (MPA). Based on their group, participants will receive Mirena, which is inserted into the uterus at the start of the study, or they will take progestins once daily by mouth for 6 months.\n\nEach participant will be in the study for around 10 months with up to 5 visits to the study clinic\u002Fsite.\n\nParticipants will visit the study clinic:\n\n* once before the treatment starts\n* 3 times with a gap of 3 months between the visits during the treatment\n* then 1 more time after the treatment ends\n\nDuring the study, the doctors and their study team will:\n\n* check participant's health by performing tests such as blood and urine tests\n* perform vaginal ultrasound and hysteroscopy. Hysteroscopy is a minor surgical procedure where a thin camera will be inserted into the womb to check for any abnormality. Sampling of the endometrial lining (cells in the womb) will be done with a thin tube at the same time.\n* take samples of womb (endometrial) lining\n* ask the participants questions about how they are feeling and what adverse events they are having\n\nAn adverse event is any medical problem that a participant has during a study. Doctors keep track of all adverse events, irrespective if they think it is related or not to the study treatment.",[27],"2026-06-22",{"date":57,"type":32},"2026-06-23",{"date":59,"type":32},"2025-11-24",{"date":61,"type":20},"2027-11-01",{"name":63,"class":64},"Bayer","INDUSTRY",89,{"id":67,"slug":68,"hasResults":11,"nctId":69,"briefTitle":70,"officialTitle":71,"acronym":72,"eligibilityCriteria":73,"healthyVolunteers":11,"sex":16,"minAge":74,"maxAge":4,"enrollmentInfo":75,"targetDuration":4,"studyType":77,"phases":4,"briefSummary":78,"conditions":79,"keywords":87,"overallStatus":97,"whyStopped":4,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":107},"100640491","measurement-of-urinary-hormones-in-patients-with-abnormal-uterine-bleeding-to-study-uterine-cancer-progression-100640491","NCT07581288","Measurement of Urinary Hormones in Patients With Abnormal Uterine Bleeding to Study Uterine Cancer Progression","Quantitative Hormonal Biomarkers of Uterine Cancer Progression in Patients With Abnormal Uterine Bleeding","MIRA","Inclusion Criteria:\n\n* 35 years and older\n* Have experienced AUB\n\nExclusion Criteria:\n\n* Currently pregnant or become pregnant during their participation\n* Previous surgeries impairing the menstrual cycle (e.g. hysterectomy, bilateral oophorectomy)\n* Currently or in the previous 3 months on medications that are known to impair or stimulate ovulation (e.g. oral contraceptives, ovulation stimulants, hormone replacement, etc.)","35 Years",{"count":76,"type":20},50,"OBSERVATIONAL","The investigators will obtain urine hormone results and validated menstrual bleeding score from people experiencing abnormal uterine bleeding. The investigators will evaluate satisfaction and ease of use of Mira monitor. The investigators will measure recruitment rate, attrition and cycle collection completeness of data. The investigators will evaluate menstrual health literacy at baseline and at the conclusion of the study.",[80,81,82,83,27,84,85,86],"Uterine Bleeding","Uterine Cancer","Uterine Neoplasms","Endometrial Cancer","Endometrial Intraepithelial Neoplasia","Menstrual Cycle","Reproductive Endocrinology",[88,89,81,90,91,92,93,94,95,96],"Digital Health","Urinary Hormones","Abnormal Uterine Bleeding","Menstrual Cycle Tracking","At-home monitoring","Follicle Stimulating Hormone","Luteinizing Hormone","Estrogen","Progesterone","NOT_YET_RECRUITING","2026-05-06",{"date":100,"type":32},"2026-05-12",{"date":102,"type":20},"2026-05",{"date":104,"type":20},"2026-09",{"name":106,"class":39},"University of British Columbia",1,{"id":109,"slug":110,"hasResults":11,"nctId":111,"briefTitle":112,"officialTitle":113,"acronym":4,"eligibilityCriteria":114,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":115,"targetDuration":4,"studyType":21,"phases":117,"briefSummary":118,"conditions":119,"keywords":121,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":129,"lastUpdatePostDateStruct":130,"startDateStruct":132,"completionDateStruct":134,"leadSponsor":136,"locationsCount":138},"100508646","phase-2-uterine-preservation-via-lifestyle-transformation-100508646","NCT05903131","Uterine Preservation Via Lifestyle Transformation","UPLifT-Endo: Uterine Preservation Via Lifestyle Transformation A Behavioral Intervention to Promote Primary Prevention and Uterine Preservation in Premenopausal Women With Obesity and Atypical Endometrial Hyperplasia or Grade 1 Endometrial Cancer","Inclusion Criteria:\n\n* Diagnosis of histologically confirmed complex atypical endometrial hyperplasia (AEH) or grade 1 endometrial cancer.\n\n  * Patients with a previous diagnosis of AEH or grade 1 endometrial cancer who are already being followed with conservative management with oral or LNG-IUD progestin therapy are eligible.\n  * For patients with a previous diagnosis of AEH or grade 1 endometrial cancer who have been placed on progestin prior to study entry, the duration of IUD or oral progestin use prior to trial entry should be documented.\n* Premenopausal woman with a uterus.\n* ECOG performance status of 0-2.\n* At least 18 years of age and no more than 45 years of age.\n* Undergoing uterine-sparing management (e.g. due to interest in fertility preservation, interest in uterine preservation, provider recommendation, or other reason).\n* BMI ≥ 30 kg\u002Fm\\^2.\n* Prior or current receipt of progestin is allowed as above. Willingness to undergo placement of LNG-IUD at the time of study entry.\n* Ability to understand and willingness to sign an IRB approved written informed consent document.\n\nExclusion Criteria:\n\n* Current, active treatment for any malignant neoplasm with chemotherapy or radiation.\n* Pregnant and\u002For breastfeeding. Participants must have a negative urine or serum pregnancy test during screening window and within 7 days prior to LNG-IUD insertion. If LNG-IUD is in place, lack of pregnancy is assumed.\n* Active pelvic infection at the time of IUD placement or other contraindication to the use of an IUD in the opinion of the treating physician.",{"count":116,"type":20},96,[23],"Up to 60% of endometrial cancer cases are attributed to obesity, in part because obesity promotes development of atypical endometrial hyperplasia (AEH), and up to 40% of women with AEH go on to develop endometrial cancer. The increasing prevalence of obesity in premenopausal women has resulted in increasing rates of AEH in this age group. Hysterectomy with removal of the fallopian tubes and ovaries is 100% effective in preventing endometrial cancer, but this approach results in infertility. Fertility-sparing treatments exist, such as treatment with oral or intrauterine progestin, but these treatments do not work uniformly and do not combat the underlying cause of endometrial cancer, which is obesity and metabolic syndrome. Additionally, up to 41% of women on progestin eventually experience relapse of AEH or endometrial cancer. Third, many patients have insulin resistance that may worsen with progestin therapy. Thus, to improve treatment of AEH and grade 1 endometrial cancer, prevent and reverse endometrial cancer, and allow women to preserve their fertility, the investigators must integrate an effective weight loss strategy to be given with progestin treatment. It is the hypothesis that premenopausal women with AEH desire uterine preservation will be more likely to have atypia-free uterine preservation at one year if they receive progestin in combination with a behavioral weight loss intervention versus progestin plus enhanced usual care.",[27,120],"Grade 1 Endometrial Cancer",[122,123,124,125,126,127,128],"fertility-sparing","weight management","obesity","endometrial cancer","behavioral intervention","premenopausal endometrial hyperplasia","premenopausal endometrial cancer","2026-01-16",{"date":131,"type":32},"2026-01-20",{"date":133,"type":32},"2024-10-24",{"date":135,"type":20},"2029-10-31",{"name":137,"class":39},"Washington University School of Medicine",3,{"id":140,"slug":141,"hasResults":11,"nctId":142,"briefTitle":143,"officialTitle":144,"acronym":145,"eligibilityCriteria":146,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":147,"targetDuration":4,"studyType":77,"phases":4,"briefSummary":149,"conditions":150,"keywords":4,"overallStatus":97,"whyStopped":4,"lastUpdateSubmitDate":155,"lastUpdatePostDateStruct":156,"startDateStruct":158,"completionDateStruct":160,"leadSponsor":162,"locationsCount":4},"100615907","cervical-cytology-dna-methylation-for-endometrial-lesion-screening-and-follow-up-100615907","NCT07298707","Cervical Cytology DNA Methylation for Endometrial Lesion Screening and Follow-up","A Multicenter Study on Cervical Cytology DNA Methylation for Screening and Follow-up of Endometrial Lesions","EndoMethy-V","Inclusion Criteria:\n\n1. Participants must be 18 years of age or older.\n2. Participants must possess medium-to-high risk factors for endometrial cancer as defined by Chinese consensus guidelines and are scheduled for hysteroscopic evaluation; OR are currently undergoing conservative treatment (e.g., progesterone therapy or endometrial ablation) for endometrial lesions, and have not received chemotherapy.\n3. Participants must be capable and willing to provide written informed consent.\n4. Participants must be willing to undergo at least one follow-up assessment within 1 year.\n5. Participants must have an intact cervix (a history of LEEP or conization is acceptable).\n\nExclusion Criteria:\n\n1. Current treatment for any gynecologic malignancy other than endometrial cancer.\n2. Current or untreated cervical, vaginal, or vulvar intraepithelial neoplasia or carcinoma.\n3. History of total or subtotal hysterectomy, trachelectomy, radical trachelectomy, or pelvic radiotherapy.\n4. Active lower genital tract bleeding.\n5. Immunosuppressed state (e.g., HIV infection, status post organ transplantation).\n6. Failure to undergo the planned hysteroscopic evaluation and follow-up within 1 year after the initial assessment.\n7. Failed hysteroscopic procedure.\n8. Any other condition that, in the opinion of the investigator, makes the participant unsuitable for inclusion in the study.",{"count":148,"type":20},3500,"The goal of this observational study is to evaluate the accuracy of a novel molecular test for screening and monitoring endometrial lesions in women at medium-to-high risk for endometrial cancer.\n\nThe main questions it aims to answer are:\n\n* What is the sensitivity and specificity of the CISENDO test (a DNA methylation test on cervical cytology samples) for detecting histologically confirmed endometrial intraepithelial neoplasia (EIN) or invasive endometrial cancer?\n* How do DNA methylation levels change during the follow-up of endometrial lesions? Researchers will compare the results of the CISENDO test to the results from the standard diagnostic procedure (hysteroscopy with histology) to see if the molecular test can reliably identify high-risk lesions and track disease progression.\n\nParticipants will:\n\n* Provide a residual liquid-based cervical cytology sample for the CISENDO test.\n* Undergo a standard diagnostic hysteroscopy examination (with or without biopsy) for comparison.\n* Some participants will return for follow-up visits at 6 and 12 months for repeat methylation testing and\u002For hysteroscopy to monitor their condition.",[151,152,153,154,27],"Endometrial Neoplasms","DNA Methylation","Cervical Smears","Early Detection of Cancer","2025-12-09",{"date":157,"type":32},"2025-12-23",{"date":159,"type":20},"2026-01-10",{"date":161,"type":20},"2026-12-31",{"name":163,"class":39},"Peking Union Medical College Hospital",{"id":165,"slug":166,"hasResults":11,"nctId":167,"briefTitle":168,"officialTitle":169,"acronym":170,"eligibilityCriteria":171,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":172,"enrollmentInfo":173,"targetDuration":175,"studyType":77,"phases":4,"briefSummary":176,"conditions":177,"keywords":181,"overallStatus":97,"whyStopped":4,"lastUpdateSubmitDate":188,"lastUpdatePostDateStruct":189,"startDateStruct":191,"completionDateStruct":193,"leadSponsor":195,"locationsCount":40},"100603498","popq-associated-with-total-laparoscopic-hysterectomy-100603498","NCT07137299","POPQ Associated With Total Laparoscopic Hysterectomy","POPQ Associated With Total Laparoscopic Hysterectomy - Multicenter Prospective Observational Study - POP-LAP STUDY","POP-LAP","Inclusion Criteria:\n\n* persons who underwent total or subtotal hysterectomy for benign conditions regardless of the type of surgery\n* agree to participate and to follow-up\n\nExclusion Criteria:\n\n* having uterus\n* health state - ECOG \\>2\n* pelvic organ prolapse prior to the surgery\n* surgery due to malignant conditions (ovarian, cervical or endometrial cancer)","85 Years",{"count":174,"type":20},2000,"10 Years","The goal of this observational study is to evaluate the impact of different hysterectomy (removal of the uterus) techniques on the risk of pelvic organ prolapse (situation when one or more of your pelvic organs like your bladder, uterus, or rectum have dropped down or slipped out of their normal position, sometimes even bulging into the vagina) and urinary incontinence (leaking urine unexpectedly) in women aged 18-85 who underwent hysterectomy or supracervical hysterectomy (removing of the uterus without its cervix) for benign (not cancer) conditions.\n\nThe main question is: to check how different surgical technique (laparoscopic, with opening the abdomen, vaginal and robotic) increase the risk of pelvic organ prolapse or urinary incontinence There is no randomization or control group; comparisons will be made between surgery types based on clinical and questionnaire data.\n\nParticipants will:\n\n* Receive an invitation to participate if they underwent hysterectomy between 2021-2025.\n* Fill out validated quality of life questionnaires (P-QOL, POPDI-6, PFIQ-7) every two years.\n* Attend follow-up clinical pelvic exams every two years to assess vaginal cuff healing, pelvic organ prolapses (POP-Q system), and urinary symptoms.\n\nThis prospective, non-commercial, multicenter study plans to enroll 2,000 women and will run from July 1, 2025, to July 1, 2036",[178,179,27,180],"Uterine Fibroids (UF)","Abnormal Uterine Bleeding Unrelated to Menstrual Cycle","Pelvic Organ Prolapse (POP)",[182,183,184,185,186,187],"Hysterectomy","Vaginal hysterectomy","Laparotomy","Laparoscopy","Robotic surgery","pelvic organ prolapse","2025-08-15",{"date":190,"type":32},"2025-08-22",{"date":192,"type":20},"2025-10-01",{"date":194,"type":20},"2037-07-01",{"name":196,"class":39},"Medical University of Silesia",{"id":198,"slug":199,"hasResults":11,"nctId":200,"briefTitle":201,"officialTitle":202,"acronym":203,"eligibilityCriteria":204,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":205,"targetDuration":4,"studyType":77,"phases":4,"briefSummary":207,"conditions":208,"keywords":212,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":218,"lastUpdatePostDateStruct":219,"startDateStruct":221,"completionDateStruct":223,"leadSponsor":224,"locationsCount":107},"100598929","surgical-and-obstetric-outcomes-in-endometrial-adenocarcinoma-and-atypical-endometrial-hyperplasia-with-conservative-treatment-100598929","NCT07077876","Surgical and Obstetric Outcomes in Endometrial Adenocarcinoma and Atypical Endometrial Hyperplasia With Conservative Treatment","Surgical and Obstetric Outcomes in Patients With Endometrial Adenocarcinoma and Atypical Endometrial Hyperplasia Undergoing Conservative Treatment","CHOICE","Inclusion Criteria:\n\n* Female patients aged 18 years or older.\n* Histological diagnosis of endometrial adenocarcinoma (EAC) or atypical endometrial hyperplasia (AEH).\n* Patients who underwent conservative treatment with hysteroscopic resection at the CLASS Hysteroscopy Center, performed by a single experienced surgeon (U.C.).\n* Patients treated conservatively due to medical contraindications to radical surgery (e.g., severe comorbidities).\n* Signed informed consent for participation in the study.\n\nExclusion Criteria:\n\n* Patients with other known causes of infertility.\n* Patients with non-endometrioid histological subtypes of endometrial adenocarcinoma.\n* Patients under 18 years of age.\n* Patients who did not provide informed consent for participation.",{"count":206,"type":20},100,"This observational study aims to evaluate the obstetric and oncological outcomes of patients diagnosed with endometrial adenocarcinoma (EAC) or atypical endometrial hyperplasia (AEH) who underwent conservative treatment at the CLASS Hysteroscopy Center of Fondazione Policlinico Universitario A. Gemelli IRCCS in Rome. Eligible patients include women who received hysteroscopic surgery and hormonal therapy either to preserve fertility or due to medical contraindications to standard radical surgery. Follow-up lasts 12 months.",[209,27,210,211],"Endometrial Adenocarcinoma","Fertility Preservation","Conservative Treatment Therapy",[83,213,214,215,216,217],"Atypical Endometrial Hyperplasia","Fertility-Sparing Treatment","Hysteroscopy","Progestin Therapy","Reproductive Outcomes","2025-07-12",{"date":220,"type":32},"2025-07-22",{"date":222,"type":32},"2025-06-20",{"date":131,"type":20},{"name":225,"class":39},"Fondazione Policlinico Universitario Agostino Gemelli IRCCS",{"id":227,"slug":228,"hasResults":11,"nctId":229,"briefTitle":230,"officialTitle":230,"acronym":231,"eligibilityCriteria":232,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":233,"enrollmentInfo":234,"targetDuration":4,"studyType":77,"phases":4,"briefSummary":235,"conditions":236,"keywords":238,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":241,"lastUpdatePostDateStruct":242,"startDateStruct":244,"completionDateStruct":246,"leadSponsor":248,"locationsCount":107},"100596658","cohort-study-of-intrauterine-diseases-100596658","NCT07048327","Cohort Study of Intrauterine Diseases","TJ Intrauterin","Inclusion Criteria:\n\n* Age: 18-80 years;\n* Patients requiring hysteroscopy or diagnostic curettage for intrauterine pathologies (e.g., endometrial hyperplasia, endometrial polyps, submucosal uterine fibroids, adenomyosis, or endometrial malignancies);\n* Willing and able to comply with follow-up requirements;\n* Signed informed consent obtained.\n\nExclusion Criteria:\n\n* Concurrent participation in other drug clinical trials;\n* Contraindications to or inability to tolerate hysteroscopy\u002Fcurettage procedures;\n* Unwilling or unable to provide informed consent;\n* Unwilling or unable to adhere to study protocols.","80 Years",{"count":174,"type":20},"\"This study employs a prospective cohort design by establishing a uterine cavity diseases research platform. The investigators will collect participants' current medical history, menstrual and obstetric history, past medical history, physical and gynecological examinations, imaging studies, laboratory tests, and pathological examinations. After the hysteroscopic surgery, the investigators will conduct a one-year follow-up on the disease progression of the participants. Through this comprehensive approach, the investigators aim to deeply investigate the pathogenesis, risk factors, and optimized treatment strategies for uterine cavity diseases.\"",[83,27,237],"Endometrial Polyps",[239,83,27,237,240],"Intrauterine diseases","Cohort Study","2025-06-24",{"date":243,"type":32},"2025-07-02",{"date":245,"type":20},"2025-07",{"date":247,"type":20},"2028-07",{"name":249,"class":39},"Wenwen Wang",{"id":251,"slug":252,"hasResults":11,"nctId":253,"briefTitle":254,"officialTitle":255,"acronym":256,"eligibilityCriteria":257,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":258,"targetDuration":4,"studyType":21,"phases":260,"briefSummary":262,"conditions":263,"keywords":265,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":268,"lastUpdatePostDateStruct":269,"startDateStruct":271,"completionDateStruct":273,"leadSponsor":275,"locationsCount":107},"100554650","pipelle-under-ultrasound-guidance-pug-to-investigate-post-menopausal-bleeding-100554650","NCT06501846","Pipelle® Under Ultrasound Guidance (PUG) to Investigate Post-menopausal Bleeding.","Pipelle® Under Ultrasound Guidance (PUG) to Investigate Post-menopausal Bleeding: Randomised Controlled Trial.","PUG","Inclusion Criteria:\n\n* All patients with post-menopausal bleeding who require an endometrial biopsy.\n\nFurther details:\n\n* Post-menopausal bleeding is defined as bleeding one year after a woman's last menstrual period or bleeding six months after starting continuous combined hormone replacement therapy.\n* There is no upper age limit, however all patients must be 18 or above.\n\nStrict ultrasound criteria will be followed:\n\n* Endometrium ≥5mm: this is the current cut off used by Imperial College Healthcare NHS Trust for a biopsy to be indicated in the context of post-menopausal bleeding.\n* Smooth, homogenous endometrium with a clearly defined border.\n\nExclusion Criteria:\n\n* Focal endometrial pathology (including but not limited to endometrial polyps, type 0-2 fibroids, uterine septa and other uterine structural abnormalities).\n* Suspicion of non-benign myometrial pathology.\n* History of endometrial cancer or endometrial hyperplasia.\n* History of cervical cancer.\n* Virgo intacta.\n* Inability to tolerate vaginal examination.\n* Inability to consent.\n* The denial or withdrawal of informed written consent.",{"count":259,"type":20},92,[261],"NA","TITLE Pipelle® under Ultrasound Guidance (PUG) to investigate post-menopausal bleeding: Randomised Controlled Trial\n\nBACKGROUND Women who are suspected of having endometrial cancer (cancer of the inner lining of the womb) due to vaginal bleeding after the menopause must have a tissue sample taken from this area to determine whether there is an abnormality.\n\nOne method of doing this is by using a small biopsy device (such as a Pipelle®) in the outpatient setting. This is referred to as an outpatient endometrial biopsy. However, a significant number of attempted endometrial biopsies are unsuccessful in obtaining a sample that is adequate for laboratory (histopathological) assessment. When an adequate sample is not obtained patients must then undergo more invasive testing.\n\nAIM This trial will use an ultrasound probe placed on the lower stomach (transabdominal ultrasound) to try and guide the doctor performing the endometrial biopsy with the aim of increasing the number of adequate samples that are obtained.\n\nThe trial will also investigate if this technique is less painful and more acceptable to patients, and if the time taken for patients to receive definitive treatment after their biopsy is reduced.\n\nELIGIBILITY All patients presenting with post-menopausal bleeding who have an endometrial thickness of 5mm or above without a contraindication to an outpatient endometrial biopsy.\n\nDESIGN Prospective randomised controlled trial enrolling 92 patients. When patients are entered into the study they will randomly assigned to one of two groups. One group will have their biopsy performed under transabdominal ultrasound guidance and the other will have the biopsy performed using the traditional 'blind' approach without ultrasound guidance. There will be 46 patients in each group.\n\nDURATION The trial will run for three years. The trial will be performed in the outpatient gynaecological oncology department at Queen Charlotte's and Chelsea Hospital, part of Imperial College Healthcare NHS Trust.",[83,264,27],"Post-Menopausal Bleeding",[266,267],"Pipelle Endometrial Biopsy","Ultrasound Guidance","2024-07-11",{"date":270,"type":32},"2024-07-15",{"date":272,"type":20},"2024-07-23",{"date":274,"type":20},"2027-07-23",{"name":276,"class":39},"Imperial College Healthcare NHS Trust",{"id":278,"slug":279,"hasResults":11,"nctId":280,"briefTitle":281,"officialTitle":282,"acronym":4,"eligibilityCriteria":283,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":284,"enrollmentInfo":285,"targetDuration":4,"studyType":21,"phases":287,"briefSummary":288,"conditions":289,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":291,"lastUpdatePostDateStruct":292,"startDateStruct":294,"completionDateStruct":296,"leadSponsor":297,"locationsCount":107},"100548187","prospective-study-for-endometrial-carcinoma-and-hyperplasia-in-childbearing-age-women-100548187","NCT06417736","Prospective Study for Endometrial Carcinoma and Hyperplasia in Childbearing-age Women","Prospective Clinical Study of Fertility-sparing Treatment With a Membrane-inhibiting Formula Combined With Oral Progestins for Endometrial Carcinoma and Hyperplasia in Childbearing-age Women","Inclusion Criteria:\n\n* 1.18-45 years old with a strong desire to preserve fertility; 2. pathologically diagnosed with primary grade1 or grade2 endometrioid endometrial carcinoma and hyperplasia 3.no signs of suspicious myometrial invasion by enhanced magnetic resonance imaging (MRI) 4. no signs of suspicious extrauterine metastasis by enhanced computed tomography and CT scan of the Lungs\n\nExclusion Criteria:\n\n* 1.have contraindication for pregnancy. 2.no fertility requiremen 3.have myometrial invasion or extrauterine metastasis 4.pathologically diagnosed with primary grade3 endometrioid endometrial carcinoma or non-endometrioid endometrial carcinoma 5.Any disease or symptom that may affect the implementation of the study or the interpretation of the results","45 Years",{"count":286,"type":20},75,[261],"The goal of this clinical trial is to evaluate the effect and adverse side effects of membrane-inhibiting formula plus oral progestins as fertility-preserving treatment in patients with early-stage endometrial cancer and endometrial hyperplasia research questions：When taken with oral progestins, does the drug membrane-inhibiting formula shorten the time required for complete endometrial remission? What medical problems do participants have when taking drug membrane-inhibiting formula plus oral progestins? Efficacy, side effects, recurrence, pregnancy, and time to obtain pregnancy in different molecular classifications of POLE-mutated, mismatch repair-deficient(MMRd), p53 wild type(p53wt), and p53-abnormal(p53abn).\n\nParticipants will: Take drug membrane-inhibiting formula plus oral progestins every day Visit the clinic once every 3 months for checkups, tests, and hysteroscopy Keep a diary of examination results and pathology",[290,27],"Endometrial Cancer Stage I","2024-05-12",{"date":293,"type":32},"2024-05-16",{"date":295,"type":32},"2023-12-01",{"date":161,"type":20},{"name":298,"class":39},"Women's Hospital School Of Medicine Zhejiang University",{"id":300,"slug":301,"hasResults":11,"nctId":302,"briefTitle":303,"officialTitle":304,"acronym":305,"eligibilityCriteria":306,"healthyVolunteers":11,"sex":16,"minAge":307,"maxAge":308,"enrollmentInfo":309,"targetDuration":4,"studyType":21,"phases":311,"briefSummary":312,"conditions":313,"keywords":315,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":319,"lastUpdatePostDateStruct":320,"startDateStruct":322,"completionDateStruct":324,"leadSponsor":325,"locationsCount":107},"100390294","fertility-sparing-management-of-endometrial-cancer-and-hyperplasia-100390294","NCT04362046","Fertility Sparing Management of EndomeTrial Cancer and Hyperplasia","Fertility Preservation Using Endomyometrial Resection for Atypical Hyperplasia and Low Grade, Stage 1A, Endometrial Cancer","FETCH","All candidates for this protocol must have an adequate trial of anti-hormone therapy prior to hysteroscopic resection. In cases of EC, the minimum trial is 6 months of high-dose progestin. In cases of AH, being that this is a benign condition (pre-malignant), patients may not require a full 6 months of anti-hormone therapy. All patients must have a pre-HR hysteroscopic evaluation to confirm that they are suitable candidates for this study. Patients being considered for the experimental intervention (hysteroscopic resection) will be reviewed and discussed by the study committee in order to ensure that the following criterion are met in order to proceed with the surgical resection:\n\nInclusion criteria:\n\n* Age less than 40 years\n* Pathologist confirmed biopsy evidence of one of the following:\n\n  1. Grade I endometrial endometrioid adrenocarcinoma (EC) with less than 1\u002F3 of the endometrial surface involved.\n  2. Atypical endometrial hyperplasia (AH)\n* MRI demonstrating less than 1\u002F3 myometrial invasion if the patient has EC\n* Absence of significant surgical co-morbidities e.g. pulmonary hypertension, significant cardiac valvular disease, or contraindication to surgery.\n* Desire to preserve fertility\n* Reasonable chance to conceive based on consultation with an infertility specialist\n* Adequate dose and duration of progesterone therapy prior to enrolment:\n* Adequate dose:\n\n  1. Medroxyprogesterone acetate (Provera; 200mg\u002Fday)\n  2. Megestrol acetate (Megace; 160mg\u002Fday)\n* Adequate duration: 6 months\n* Failure of progestin therapy defined as:\n\n  1. Unsuccessful eradication of hyperplasia or cancer in the uterus\n  2. Intolerance to the side effects\n* Signed informed consent\n\nExclusion criteria:\n\n* Age 40 years and over\n* Grade 2 or 3 endometrioid endometrial adenocarcinoma or non-endometrioid pathology\n* Greater than 1\u002F3 involvement of the endometrial surface in patients with Grade I EC\n* Women who are not able to provide informed consent\n* Women without pathologic confirmation of low-grade endometrioid carcinoma or AH\n* Myometrial invasion on MRI greater than 1\u002F3 total myometrial thickness.\n* MRI evidence of ovarian or adnexal involvement\n* The diagnosis of another cancer or medical condition that would interfere with the assessment of the hysteroscopic surgery success rates.\n* Significant underlying fertility impairment that would significantly interfere with the success rate of HR","19 Years","39 Years",{"count":310,"type":20},30,[261],"This study protocol evaluates the use of hysteroscopic endomyometrial resection in women diagnosed with atypical endometrial hyperplasia or grade I endometrial cancer who have not responded to anti-hormone therapy. Patients in this study wish to preserve fertility.",[27,83,314],"Gynecologic Cancer",[316,317,318],"Fertility preservation","Hysteroscopic uterine resection","High-dose progesterone","2021-10-14",{"date":321,"type":32},"2021-10-20",{"date":323,"type":32},"2020-11-15",{"date":247,"type":20},{"name":326,"class":39},"Vancouver Coastal Health Research Institute"]